Astellas and Sangamo Therapeutics Partner for Administering Genomic Therapies Targeting Neurological Disorders
Shots:
- Sangamo licensed the global rights for the use of STAC-BBB capsid (has depicted BBB penetration ability) to Astellas for 1 target, with option to add 4 more (on paying additional licensed target fees), for administering genomic therapies (IV) targeting neurological disorders
- As per the agreement, Sangamo is entitled for $20M upfront, additional over $1.3B as licensed target fees, milestones for 5 targets and net-sales-based tiered mid-to-high single digit royalties
- Sangamo will complete STAC-BBB capsid associated technology transfer while Astellas will handle all research, development, manufacturing, regulatory events & worldwide commercialization of the gene therapies
Ref: Astellas | Image: Astellas & Sangamo
Related News:- Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
